In addition, in various cancer types like NSCLC, breast, colorectal, bladder, gastric, and esophageal cancers, HER2 mutations, particularly exon 20 insertions, lead to constitutive tyrosine kinase activation, driving oncogenesis without ligand stimulation (3, 5, 20–23). The gene discussed is ERBB2; the disease is cancer.